P13.07 * HYPO-FRACTIONATED IMRT FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
نویسندگان
چکیده
منابع مشابه
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
PURPOSE To report toxicity and overall survival (OS) in patients with newly diagnosed glioblastoma multiforme (GBM) treated with hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent and adjuvant temozolomide (TMZ). METHODS AND MATERIALS Patients with newly diagnosed GBM after biopsy or resection and with adequate performance status and organ or bone marrow function we...
متن کاملCurrent Advances in Radiotherapy for Newly Diagnosed Glioblastoma Multiforme
Copyright: © 2014 Okonogi N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
متن کاملBevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
BACKGROUND Patients with a newly diagnosed glioblastoma multiforme (GBM) have a high risk of recurrent disease with a dismal outcome despite intensive treatment of sequential surgery and chemoradiotherapy with temozolomide (TMZ), followed by TMZ as a single agent. Bevacizumab (BV) may increase response rates to chemotherapy in the recurrent treatment setting of GBM. We hypothesized that a neoad...
متن کاملA pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.
PURPOSE To define the maximum tolerated dose (MTD) of lenalidomide, an analogue of thalidomide with enhanced immunomodulatory and antiangiogenic properties and a more favorable toxicity profile, in patients with newly diagnosed glioblastoma multiforme (GBM) when given concurrently with radiotherapy. PATIENTS AND METHODS Patients with newly diagnosed GBM received radiotherapy concurrently with...
متن کاملLongitudinal MRSI study in newly diagnosed Glioblastoma Multiforme
Introduction Glioblastoma Multiforme (GBM) is the most common and the most malignant type of glioma. Despite the advances in multimodality treatments that combine surgery, radiation and chemotherapy, patients with GBM have a limited prognosis, with a median survival of one year. The standard criteria for assessing tumor progression and response to therapy are based upon changes in cross section...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-Oncology
سال: 2014
ISSN: 1522-8517,1523-5866
DOI: 10.1093/neuonc/nou174.253